Why try to beat 'em if you can just buy 'em? That's the approach that Questcor Pharmaceuticals (NASDAQ: QCOR ) is taking. The biotech announced today that it has acquired rights to develop Syncathen and�Synacthen Depot in the U.S. from�Novartis (NYSE: NVS ) . Questcor is paying $60 million up front and at least $75 million over the next few years, plus potential milestone payments. Shares were up nearly 25% in early trading.
What it means
Questcor appears to be playing both defense and offense with this move. On the defensive front, buying rights to Synacthen makes a lot of sense. Synacthen is a synthetic version of adrenocorticotropic hormone, or ACTH, which is the active ingredient in Acthar.
There's at least one big difference between Acthar and Synacthen, though. Questcor charges $28,000 per vial for Acthar. Synacthen Depot sells for around 3% of the cost of Acthar. You read that right -- Acthar costs 30 times more than the its synthetic rival.
5 Best Supermarket Stocks To Buy For 2015: UnipolSai Assicurazioni SpA (US)
UnipolSai Assicurazioni SpA, formerly Fondiaria SPA, is an Italy- based company engaged in financial sector. The Company is a result of the merger of Unipol Assicurazioni SpA, Milano Assicurazioni SpA and Premafin Finanziaria SpA into Fondiaria Sai SpA. The Company operates through approximately 3 000 agencies under brands, such as Unipol, Sai, La Fondaria, Milano, La Previdente, Nuova Maa and Sasa. UnipolSai Assicurazioni SpA specializes in non-life insurance, especially automobile insurance. Additionally, UnipolSai Assicurazioni SpA provides products which protect its clients against damage and accident in the field, such as work, home, travel, health, life, aviation, railway, fire, maritime and goods in transit, as well as reinsurance and legal protection. Advisors' Opinion:- [By Nicolas Johnson]
There are a couple of reasons money managers often advise Canadian investors to overcome their home-country bias and to put part of their assets abroad. One goal is to get a chance at higher returns by investing in expanding businesses or industries that are absent from our own stock exchanges. Canada's stock market represents only about 3.4% of the world's $62-trillion (US) in publicly traded companies. A second goal is to diversify wealth and reduce the vulnerability of one's portfolio to a collapse in the Canadian market.
Top 5 Defensive Companies To Buy For 2014: Mylan Inc (MYL)
Mylan Inc. (Mylan), incorporated in 1970, is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The Company operates a specialty business, which is focused on respiratory, allergy and psychiatric therapies. Through Mylan Laboratories Limited, an Indian subsidiary, it manufactures and supply active pharmaceutical ingredient (API) for its own products and pipeline, as well as for third parties. On December 23, 2011, Mylan completed the acquisition of rights to develop, manufacture and commercialize a generic equivalent to GlaxoSmithKline�� Advair Diskus and Seretide Diskus incorporating Pfizer Inc.��, (Pfizer) dry powder inhaler delivery platform (the Respiratory Delivery Platform). In February 2012, Valeant Pharmaceuticals International, Inc. announced that it has completed the divestiture of 1% clindamycin and 5% benzoyl peroxide gel (IDP-111), a generic version of Benzaclin, and 5% fluorouracil cream, (5-FU), an authorized generic of Efudex, to the Company.
As of December 31, 2011, Mylan marketed a global portfolio of approximately 1,100 different products covering a range of therapeutic categories. It offers a range of dosage forms and delivery systems, including oral solids, topicals, liquids and semi-solids. In addition, it focuses on transdermal patches, high potency formulations, injectables, controlled release and respiratory delivery products. Mylan operates in two segments: Generics and Specialty. Its revenues are derived from the sale of generic and branded generic pharmaceuticals, specialty pharmaceuticals and API. Its generic pharmaceutical business is conducted in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA), and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its API business is conducted through Mylan Laboratories Limited, which is included within the Asia Pacific region in its Generi! cs segment. Its specialty pharmaceutical business is conducted by Dey Pharma, L.P. (Dey).
Generics Segment
The Company sales in the United States are derived through its wholly owned subsidiary Mylan Pharmaceuticals Inc. (MPI), its primary United States pharmaceutical research, development, manufacturing, marketing and distribution subsidiary, as well as through Mylan Institutional (MI). MPI�� net revenues are derived from the sale of solid oral dosage and transdermal patch products. MI�� net revenues are derived from the sale of its unit dose and injectable product offerings. In the United States, it has product portfolios consisting of approximately 340 products, of which approximately 305 are in capsule or tablet form in an aggregate of approximately 740 dosage strengths. Included in these totals are approximately 40 extended release products in a total of approximately 105 dosage strengths. Also included in it�� the United States product portfolio are four transdermal patch products in a total of 18 dosage strengths, which are developed and manufactured by Mylan Technologies, Inc. (MTI), its wholly owned transdermal technology subsidiary, and marketed and distributed by MPI.
The Company�� North America revenues also include those generated by its wholly owned subsidiary Mylan Pharmaceuticals ULC (MPC), which markets generic pharmaceuticals in Canada. MPC offers a portfolio of approximately 115 products in an aggregate of approximately 250 dosage strengths. Its generic pharmaceutical sales in EMEA are generated by its wholly owned subsidiaries in Europe, through which it has operations in 21 countries.
In France, through the Company�� subsidiary Mylan S.A.S., it markets a retail portfolio of approximately 215 products in an aggregate of approximately 455 dosage strengths. In Italy, it markets through its subsidiary Mylan S.p.A. a portfolio of approximately 150 products in an aggregate of approximately 285 dosage strengths. In Italy, it h! as market! share, based on value and volume, in the company-branded generic retail prescription market. In Spain, it markets through its subsidiary Mylan Pharmaceuticals S.L. a portfolio of approximately 100 products in an aggregate of approximately 220 dosage strengths. In Germany, it markets through its subsidiary Mylan dura a portfolio of approximately 150 products in an aggregate of approximately 330 dosage strengths. In the United Kingdom, it offers a product portfolio of approximately 175 products in an aggregate of approximately 315 dosage strengths. It markets generic pharmaceuticals in Asia Pacific through subsidiaries in Australia, New Zealand, India, Japan and Taiwan.
In Australia, the Company offers a portfolio of approximately 170 products in an aggregate of approximately 440 dosage strengths. Mylan Seiyaku, its wholly owned Japanese subsidiary, offers a portfolio of more than 380 products in an aggregate of approximately 500 dosage strengths. At Mylan Laboratories Limited, its dosage business produces antiretroviral (ARV) products, which are sold outside of India, and other finished dosage form (FDF) products, which are sold to third parties by other Mylan operations globally. In addition, Mylan Laboratories Limited offers a line of FDF products in the ARV market and manufactures non-ARV FDF products that are marketed by Mylan.
Specialty Segment
The Company�� specialty pharmaceutical business is conducted through Dey. Dey�� portfolio consists of branded specialty injectable, nebulized and transdermal products for life-threatening conditions. Dey�� revenues are derived through the sale of the EpiPen Auto-Injector. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector that has been sold in the United States and internationally.
Advisors' Opinion:- [By Ben Levisohn]
Mylan (MYL) has gained 5.8% to $49.19 after the drug maker boosted its third-quarter earnings guidance to a between $1.12 and $1.16, up from a range of 90 cents to 95 cents.
Top 5 Defensive Companies To Buy For 2014: The First of Long Island Corporation(FLIC)
The First of Long Island Corporation operates as a bank holding company for The First National Bank of Long Island that provides various financial services. It offers various deposit products, including checking, money market, savings, escrow service and interest on lawyer, time deposit, NOW, rent security, holiday club, and individual retirement accounts. The company?s loan portfolio consists of commercial and industrial loans; residential and commercial mortgage loans; home equity loans and lines; multifamily loans; construction loans; consumer loans, such as auto and home improvement loans, personal loans, overdraft checking lines, and credit cards; commercial loans, which include short-term business loans, term and installment loans, revolving credit term loans, and loans secured by marketable securities, general business assets, deposits, and surrender value of life insurance policies; and commercial and standby letters of credit. In addition, it provides account rec onciliation, ATM banking, bank by mail, bill payment, cash management, collection, drive-through banking, personal money orders, Internet and telephone banking, merchant credit card depository, lock box, night depository, payroll, remote deposit, securities transactions, signature guarantee, trust and investment management, wire transfers and foreign cables, and withholding tax depository services, as well as offers controlled disbursement accounts, travelers and counter checks, mutual funds, annuities, life insurance and securities, safe deposit boxes, and the U.S. savings bonds. Further, the company provides pension trust, personal trust, estate, and custody services; and insurance agency services, as well as owns a real estate investment trust. It offers its services to privately owned businesses, professionals, consumers, public bodies, and other organizations through its 34 branches primarily in Long Island and Manhattan. The company was founded in 1927 and is based in Glen Head, New York.
Advisors' Opinion:- [By Dividends4Life]
The First of Long Island Corporation (FLIC) operates as a bank holding company for The First National Bank of Long Island that provides financial services. Sept. 19, the company increased its quarterly dividend 4% to $0.26 per share. The dividend is payable Oct. 11, 2013 to shareholders of record on October 3, 2013. The yield based on the new payout is 2.7%.
Top 5 Defensive Companies To Buy For 2014: Kindred Healthcare Inc. (KND)
Kindred Healthcare, Inc. operates as a healthcare services company in the United States. The company�s Hospital division operates long-term acute care (LTAC) and inpatient rehabilitation (IRFs) hospitals, which provide services to medically complex patients, including the critically ill, suffering from multiple organ system failures, primarily the cardiovascular, pulmonary, kidney, gastro-intestinal, and skin systems, as well as life-threatening infections. Its Nursing Center division operates nursing and rehabilitation centers, and assisted living facilities that offer short stay patients and long stay residents with a range of medical, nursing, rehabilitative, pharmacy, and routine services. It also provides specialized programs for residents suffering from Alzheimer�s disease and other dementias through its reflections units. The company�s Rehabilitation division provides rehabilitation services, including physical and occupational therapies, and speech pathology ser vices under the RehabCare name to residents and patients of nursing centers, LTAC hospitals, outpatient clinics, home health agencies, assisted living facilities, school districts, and hospice providers. In addition, it offers specialized care programs that address medical needs, such as wound care, pain management, and cognitive retraining; and programs for neurologic, orthopedic, cardiac, and pulmonary conditions. Its Home Health and Hospice division offers home health, hospice, and private duty services to patients in various settings comprising homes, skilled nursing facilities, and other residential settings. As of December 31, 2011, it operated 121 LTAC hospitals with 8,597 licensed beds, and 5 IRFs with 183 licensed beds in 26 states; and 224 nursing and rehabilitation centers with 27,148 licensed beds, and 6 assisted living facilities with 413 licensed beds in 27 states. The company was founded in 1998 and is headquartered in Louisville, Kentucky.
Advisors' Opinion:- [By Anna Prior]
Kindred Healthcare Inc.(KND) boosted its offer to about $589 million to buy a smaller stake in Gentiva Health Services Inc.(GTIV), as it tries to draw the home health-care company to the negotiating table.
- [By Brad Thomas]
As the only healthcare REIT with a "hospital-focused" platform, MPW is a relatively new REIT that was formed (in 2004) to lease from many of the nation's leading hospital operators, including Prime Healthcare Services, Kindred Healthcare (KND), HealthSouth (HLS), Health Management Associates (HMA), Community Health Systems (CYH), Vibra Healthcare, Ernest Health Inc., and IASIS Healthcare.
- [By Erin McCarthy]
Gentiva Health Services Inc.(GTIV) confirmed Thursday that its board has rejected Kindred Healthcare Inc.'s(KND) $533 million takeover bid, saying the proposal significantly undervalues the company.
No comments:
Post a Comment